EGTX.ST实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 23:29):

Stats
今日成交量	568 552
平均成交量	344 445
市值	1.68B
EPS	SEK0 ( 2024-02-21 )
下一个收益日期	( SEK-0.310 ) 2024-05-02
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-4.42
ATR14	SEK0.0250 (0.43%)

音量相关性

長: 0.28 (neutral)

短: 0.60 (weak)

Signal:(59.783) Neutral

Egetis Therapeutics AB 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Egetis Therapeutics AB 相关性 - 货币/商品

-0.45
( neutral )

-0.31
( neutral )

0.00
( neutral )

-0.37
( neutral )

-0.10
( neutral )

0.71
( moderate )

Egetis Therapeutics AB 财务报表

Annual	2023
营收:	SEK57.60M
毛利润:	SEK-126.80M (-220.14 %)
EPS:	SEK-1.270

FY	2023
营收:	SEK57.60M
毛利润:	SEK-126.80M (-220.14 %)
EPS:	SEK-1.270

FY	2023
营收:	SEK0
毛利润:	SEK0 (0.00 %)
EPS:	SEK0

FY	2022
营收:	SEK22.50M
毛利润:	SEK-120.10M (-533.78 %)
EPS:	SEK-0.980

Financial Reports:

No articles found.

Egetis Therapeutics AB

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

实时更新： Egetis Therapeutics AB [EGTX.ST]

Upcoming Earnings Alert